Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer

RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the oth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2020-03, Vol.38 (7), p.706-714
Hauptverfasser:	Bradley, Jeffrey D, Hu, Chen, Komaki, Ritsuko R, Masters, Gregory A, Blumenschein, George R, Schild, Steven E, Bogart, Jeffrey A, Forster, Kenneth M, Magliocco, Anthony M, Kavadi, Vivek S, Narayan, Samir, Iyengar, Puneeth, Robinson, Clifford G, Wynn, Raymond B, Koprowski, Christopher D, Olson, Michael R, Meng, Joanne, Paulus, Rebecca, Curran, Jr, Walter J, Choy, Hak
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Cetuximab - administration & dosage Chemoradiotherapy Dose Fractionation, Radiation Dose-Response Relationship, Radiation Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Neoplasm Staging ORIGINAL REPORTS Paclitaxel - administration & dosage Progression-Free Survival Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!